` CRGX (CARGO Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

CRGX
vs
S&P 500

Over the past 12 months, CRGX has underperformed S&P 500, delivering a return of -71% compared to the S&P 500's 9% growth.

Stocks Performance
CRGX vs S&P 500

Loading
CRGX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CRGX vs S&P 500

Loading
CRGX
S&P 500
Difference
www.alphaspread.com

Performance By Year
CRGX vs S&P 500

Loading
CRGX
S&P 500
Add Stock

Competitors Performance
CARGO Therapeutics Inc vs Peers

S&P 500
CRGX
ABBV
AMGN
GILD
VRTX
Add Stock

CARGO Therapeutics Inc
Glance View

Market Cap
200.6m USD
Industry
Biotechnology

CARGO Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 74 full-time employees. The company went IPO on 2023-11-10. CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The firm is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, CRG-022, is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The firm is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The firm is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.

CRGX Intrinsic Value
7.98 USD
Undervaluation 46%
Intrinsic Value
Price
C
Back to Top